Table 3.
Tyrosine-kinase inhibitor (TKI) therapy stratified for receptor tyrosine-kinase (RTK) mutation for the n = 49 patients with confirmed RTK mutation, TKI therapy, and stage IV cancer at data assessment
| TKI drug | EGFRa (N = 30) | ALKb (N = 15) | ROS1c (N = 4) |
|---|---|---|---|
| Afatinib | 9 | – | – |
| Gefitinib | 6 | – | – |
| Erlotinib | 22 | 2 | 1 |
| Crizotinib | 0 | 13 | 4 |
| Nintedanib | 1 | – | – |
| Buparlisib | – | – | – |
| Alectinib | – | 1 | – |
| ARQ197 | 1 | – | – |
| Ceritinib | – | 3 | – |
| Osimertinib | 2 | – | – |
| PTK/ZK | – | 1 | – |
| Rociletinib | 2 | – | – |
| Carbozantinib | – | – | 1 |
| LDK378 | – | 1 | – |
aEpidermal growth factor receptor (EGRF) mutations
bAnaplastic lymphoma kinase gene (ALK) rearrangements
cProto-oncogene receptor tyrosine-kinase (ROS1) rearrangements